HBM Holdings (2142) Fundamentals 2026 — P/E 23.1x, Revenue Analysis | SniperIQ
HBM Holdings (2142) is a CN-listed Healthcare company in Biotechnology with a market capitalization of HK
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is HBM Holdings's market cap?
HBM Holdings (2142) has a market capitalization of approximately HK
What is HBM Holdings's P/E ratio?
HBM Holdings's trailing twelve-month P/E ratio is 23.1x, with a price-to-book (P/B) of 3.7x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is HBM Holdings?
HBM Holdings runs a net profit margin of 51.7%, a gross margin of 92.8%, and an operating margin of 43.3%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does HBM Holdings generate?
HBM Holdings reported revenue of
Does HBM Holdings pay a dividend?
HBM Holdings does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is HBM Holdings financially healthy?
HBM Holdings carries a debt-to-equity ratio of 0.22x and a current ratio of 5.17x, with a market beta of 1.33. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is HBM Holdings a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For HBM Holdings (2142) the key facts are: market cap HK
Track HBM Holdings's full fundamentals live
Get HBM Holdings's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.